Atelocollagen-mediated intravenous siRNA delivery specific to tumor tissues orthotopically xenografted in prostates of nude mice and its anticancer effects

Nucleic Acid Therapeutics

Volumn 25, Issue 2, 2015, Pages 85-94

  Yuan, Yuan ^a   Makita, Naoki ^b   Cao, Dongliang ^a   Mihara, Keichiro ^c   Kadomatsu, Kenji ^a   Takei, Yoshifumi ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ATELOCOLLAGEN; CISPLATIN; PROTEIN BCL XL; SMALL INTERFERING RNA; VASCULOTROPIN A;

ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CELL DEATH; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE DELIVERY SYSTEM; HUMAN; HUMAN CELL; LIVER METASTASIS; MALE; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROSTATE; PROSTATE TUMOR; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR MODEL; TUMOR XENOGRAFT;

MUS MUSCULUS;

EID: 84964284460     PISSN: 21593337     EISSN: 21593345     Source Type: Journal    
DOI: 10.1089/nat.2014.0526     Document Type: Article

References (45)

1. Castanotto D JJ Rossi. (2009). The promises and pitfalls of RNA-interference-based therapeutics. Nature 457:426-433.
2. Miele E, GP Spinelli, E Miele, E Di Fabrizio, E Ferretti, S Tomao and A Gulino. (2012). Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy. Int J Nanomedicine 7:3637-3657.
3. Santel A, M Aleku, O Keil, J Endruschat, V Esche, B Durieux, K Löffler, M Fechtner, T Röhl, G Fisch, S Dames, W Arnold, K Giese, A Klippel and J Kaufmann. (2006). RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy. Gene Ther 13:1360-1370.
4. Bilensoy E. (2010). Cationic nanoparticles for cancer therapy. Expert Opin Drug Deliv 7:795-809.
5. Urban-Klein B, S Werth, S Abuharbeid, F Czubayko and A Aigner. (2005). RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther 12:461-466.
6. Hu-Lieskovan S, JD Heidel, DW Bartlett, ME Davis and TJ Triche. (2005). Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res 65:8984-8992.
7. Howard KA, UL Rahbek, X Liu, CK Damgaard, SZ Glud, MØ Andersen, MB Hovgaard, A Schmitz, JR Nyengaard, F Besenbacher and J Kjems. (2006). RNA interference in vitro and in vivo using a novel chitosan/siRNA nano-particle system. Mol Ther 14:476-484.
8. Ofek P, W Fischer, M Calderón, R Haag and R Satchi-Fainaro. (2010). In vivo delivery of small interfering RNA to tumors and their vasculature by novel dendritic nano-carriers. FASEB J 24:3122-3134.
9. Ochiya T, Y Takahama, S Nagahara, Y Sumita, A Hisada, H Itoh, Y Nagai and M Terada. (1999). New delivery system for plasmid DNA in vivo using atelocollagen as a carrier material: the Minipellet. Nat Med 5:707-710.
10. Takei Y and K Kadomatsu. (2005). In vivo delivery technique of nucleic acid compounds using atelocollagen: its use in cancer therapeutics targeted at the heparin-binding growth factor midkine. Gene Ther Mol Biol 9:257-264.
11. Fujimoto I and Y Takei. (2014). Atelocollagen-mediated siRNA delivery: future promise for therapeutic application. Ther Deliv 5:369-371.
12. Takei Y, K Kadomatsu, S Matsuo, H Itoh, K Nakazawa, S Kubota and T Muramatsu. (2001). Antisense oligodeox-ynucleotide targeted to Midkine, a heparin-binding growth factor, suppresses tumorigenicity of mouse rectal carcinoma cells. Cancer Res 61:8486-8491.
13. Takei Y, K Kadomatsu, H Itoh, W Sato, K Nakazawa, S Kubota and T Muramatsu. (2002). 5¢-, 3¢-inverted thymi-dine-modified antisense oligodeoxynucleotide targeting midkine. Its design and application for cancer therapy. J Biol Chem 277:23800-23806.
14. Takei Y, K Kadomatsu, K Yuasa, W Sato and T Mur-amatsu. (2005). Morpholino antisense oligomer targeting human midkine: its application for cancer therapy. Int J Cancer 114:490-497.
15. Takei Y, K Kadomatsu, Y Yuzawa, S Matsuo and T Muramatsu. (2004). A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res 64:3365-3370.
16. Takei Y, K Kadomatsu, T Goto and T Muramatsu. (2006). Combinational antitumor effect of siRNA against midkine and paclitaxel on growth of human prostate cancer xeno-grafts. Cancer 107:864-873.
17. Mu P, S Nagahara, N Makita, Y Tarumi, K Kadomatsu and Y Takei. (2009). Systemic delivery of siRNA specific to tumor mediated by atelocollagen: Combined therapy using siRNA targeting Bcl-xL and cisplatin against prostate cancer. Int J Cancer 125:2978-2990.
18. Minakuchi Y, F Takeshita, N Kosaka, H Sasaki, Y Ya-mamoto, M Kouno, K Honma, S Nagahara, K Hanai, A Sano, T Kato, M Terada and T Ochiya. (2004). Atelo-collagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res 32:e109.
19. Azuma K, K Nakashiro, T Sasaki, H Goda, J Onodera, N Tanji, M Yokoyama and H Hamakawa. (2010). Anti-tumor effect of small interfering RNA targeting the androgen receptor in human androgen-independent prostate cancer cells. Biochem Biophys Res Commun 391:1075-1079.
20. Sasaki T, K Nakashiro, H Tanaka, K Azuma, H Goda, S Hara, J Onodera, I Fujimoto, N Tanji, M Yokoyama and H Hamakawa. (2010). Knockdown of Akt isoforms by RNA silencing suppresses the growth of human prostate cancer cells in vitro and in vivo. Biochem Biophys Res Commun 399:79-83.
21. Teicher BA. (2006). Tumor models for efficacy determination. Mol Cancer Ther 5:2435-2443.
22. Inaba S, S Nagahara, N Makita, Y Tarumi, T Ishimoto, S Matsuo, K Kadomatsu and Y Takei. (2012). Atelocollagen-mediated systemic delivery prevents immunostimulatory adverse effects of siRNA in mammals. Mol Ther 20:356-366.
23. Ishimoto T, Y Takei, Y Yuzawa, K Hanai, S Nagahara, Y Tarumi, S Matsuo and K Kadomatsu. (2008). Down-regulation of monocyte chemoattractant protein-1 involving short interfering RNA attenuates hapteninduced contact hypersensitivity. Mol Ther 16:387-395.
24. Singh RP, K Raina, G Deep, D Chan and R Agarwal. (2009). Silibinin suppresses growth of human prostate carcinoma PC-3 orthotopic xenograft via activation of extracellular signal-regulated kinase 1/2 and inhibition of signal transducers and activators of transcription signaling. Clin Cancer Res 15:613-621.
25. Tuomela JM, MP Valta, K Väänänen and PL Härkönen. (2008). Alendronate decreases orthotopic PC-3 prostate tumor growth and metastasis to prostate-draining lymph nodes in nude mice. BMC Cancer 8:81.
26. Takei Y, T Nemoto, P Mu, T Fujishima, T Ishimoto, Y Hayakawa, Y Yuzawa, S Matsuo, T Muramatsu and K Kadomatsu. (2008). In vivo silencing of a molecular target by short interfering RNA electroporation: tumor vascularization correlates to delivery efficiency. Mol Cancer Ther 7:211-221.
27. Bartlett DW, H Su, IJ Hildebrandt, WA Weber and ME Davis. (2007). Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci USA 104:15549-15554.
28. Maeda H. (2014). Research spotlight: emergence of EPR effect theory and development of clinical applications for cancer therapy. Ther Deliv 5:627-630.
29. Senger DR, CA Perruzzi, J Feder and HF Dvorak. (1986). A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 46:5629-5632.
30. Satchi-Fainaro R, R Mamluk, L Wang, SM Short, JA Nagy, D Feng, AM Dvorak, HF Dvorak, M Puder, D Mukho-padhyay and J Folkman. (2005). Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin. Cancer Cell 7:251-261.
31. Jemal A, R Siegel, E Ward, Y Hao, J Xu and MJ Thun. (2009). Cancer statistics, 2009. CA Cancer J Clin 59:225-249.
32. Hadaschik BA and ME Gleave. (2007). Therapeutic options for hormone-refractory prostate cancer in 2007. Urol Oncol 25:413-419.
33. Feldman BJ and D Feldman. (2001). The development of androgen-independent prostate cancer. Nat Rev Cancer 1:34-45.
34. Tannock IF, R de Wit, WR Berry, J Horti, A Pluzanska, KN Chi, S Oudard, C Théodore, ND James, I Turesson, MA Rosenthal and MA Eisenberger. (2004). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512.
35. de Bono JS, S Oudard, M Ozguroglu, S Hansen, JP Ma-chiels, I Kocak, G Gravis, I Bodrogi, MJ Mackenzie, L Shen, M Roessner, S Gupta and AO Sartor. (2010). Pre-dnisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after doc-etaxel treatment: a randomised open-label trial. Lancet 376:1147-1154.
36. Gjertsen BT, CJ Logothetis and TJ McDonnell. (1999). Molecular regulation of cell death and therapeutic strategies for cell death induction in prostate carcinoma. Cancer Metastasis Rev 17:345-351.
37. Boise LH, M González-Garćia, CE Postema, L Ding, T Lindsten, LA Turka, X Mao, G Nunez and CB Thompson. (1993). bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74:597-608.
38. Karnak D and L Xu. (2010). Chemosensitization of prostate cancer by modulating Bcl-2 family proteins. Curr Drug Targets 11:699-707.
39. Parrondo R, A de Las Pozas, T Reiner and C Perez-Stable. (2013). ABT-737, a small molecule Bcl-2/Bcl-xL antagonist, increases antimitotic-mediated apoptosis in human prostate cancer cells. Peer J 1:e144.
40. You OH, SH Kim, B Kim, EJ Sohn, HJ Lee, BS Shim, M Yun, BM Kwon and SH Kim. (2013). Ginkgetin induces apoptosis via activation of caspase and inhibition of survival genes in PC-3 prostate cancer cells. Bioorg Med Chem Lett 23:2692-2695.
41. Maeda H, J Wu, T Sawa, Y Matsumura and K Hori. (2000). Tumor vascular permeability and the EPR effect in mac-romolecular therapeutics: a review. J Control Release 65:271-284.
42. Sheikh H, H Yarwood, A Ashworth and CM Isacke. (2000). Endo180, an endocytic recycling glycoprotein related to the macrophage mannose receptor is expressed on fibroblasts, endothelial cells and macrophages and functions as a lectin receptor. J Cell Sci 113:1021-1032.
43. Wienke D, JR MacFadyen and CM Isacke. (2003). Identification and characterization of the endocytic transmem-brane glycoprotein Endo180 as a novel collagen receptor. Mol Biol Cell 14:3592-3604.
44. Wienke D, GC Davies, DA Johnson, J Sturge, MB Lam-bros, K Savage, SE Elsheikh, AR Green, IO Ellis, D Robertson, JS Reis-Filho and CM Isacke. (2007). The collagen receptor Endo180 (CD280) Is expressed on basal-like breast tumor cells and promotes tumor growth in vivo. Cancer Res 67:10230-10240.
45. Ikenaga N, K Ohuchida, K Mizumoto, S Akagawa, K Fu-jiwara, D Eguchi, S Kozono, T Ohtsuka, S Takahata and M Tanaka. (2012). Pancreatic cancer cells enhance the ability of collagen internalization during epithelial-mesenchymal transition. PLoS One 7:e40434.